Impaired fasting glucose (IFG) is frequently present in hypertensive patients and might be induced or aggravated by antihypertensive treatment. However, it is unclear whether IFG is associated with increased cardiovascular risk in this population.
Patients and Methods:
We performed a cross-sectional study in 1,810 hypertensive patients and recorded the presence of IFG, coronary heart disease (CHD), and ischemic stroke.
Results:
IFG was present in 567 patients (31.3%). The prevalence of CHD or ischemic stroke did not differ between patients with IFG and in patients with serum glucose levels <100 mg/dL. Among patients with IFG, 267 (47.0%) were on β-blockers, diuretics, or both β-blockers and diuretics. The prevalence of CHD was numerically but not significantly higher in patients with IFG treated with β-blockers or both β-blockers and diuretics than in patients with IFG treated with diuretics or not treated with either β-blockers or diuretics and patients with serum glucose levels <100 mg/dL (11.1%, 13.6%, 1.4%, 3.7%, and 5.9%, respectively; P=not significant). The prevalence of ischemic stroke did not differ among these groups.
Conclusions:
IFG does not appear to be associated with increased prevalence of cardiovascular disease in hypertensive patients, regardless if it is associated with the antihypertensive treatment or not.
Get full access to this article
View all access options for this article.
References
1.
American Diabetes Association:. Standards of medical care in diabetes—2012. Diabetes Care, 2012; 35,Suppl 1:S11–S63.
2.
CowieCC, RustKF, FordES, EberhardtMS, Byrd-HoltDD, LiC, WilliamsDE, GreggEW, BainbridgeKE, SaydahSH, GeissLS. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988–1994 and 2005–2006. Diabetes Care, 2009; 32:287–294.
3.
SecreeR, ShawJ, ZimmetP. Diabetes and impaired glucose tolerance: prevalence and projections. AllgotB, GanD, KingH, LefebvreP, MbanyaJC, SilinkM. Diabetes Atlas, 2nd. Brussels: International Diabetes Federation, 2003; 17–71.
4.
Centers for Disease Control and Prevention: National diabetes fact sheet. 2011. www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. 2013 March 1.
5.
GersteinHC, SantaguidaP, RainaP, MorrisonKM, BalionC, HuntD, YazdiH, BookerL. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract, 2007; 78:305–312.
6.
KannelWB, McGeeDL. Diabetes and cardiovascular risk factors: the Framingham Study. Circulation, 1979; 59:8–13.
7.
StamlerJ, VaccaroO, NeatonJD, WentworthD. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care, 1993; 16:434–444.
8.
HaffnerSM, LehtoS, RönnemaaT, PyöräläK, LaaksoM. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 1998; 339:229–234.
9.
Emerging Risk Factors Collaboration. SarwarN, GaoP, SeshasaiSR, GobinR, KaptogeS, Di AngelantonioE, IngelssonE, LawlorDA, SelvinE, StampferM, StehouwerCD, LewingtonS, PennellsL, ThompsonA, SattarN, WhiteIR, RayKK, DaneshJ. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet, 2010; 375:2215–2222.
Dell'OmoG, PennoG, Del PratoS, MarianiM, PedrinelliR. Dysglycaemia in non-diabetic hypertensive patients: comparison of the impact of two different classifications of impaired fasting glucose on the cardiovascular risk profile. J Hum Hypertens, 2009; 23:332–338.
12.
EganBM, ZhaoY, AxonRN. US trends in prevalence, awareness, treatment, and control of hypertension, 1998–2008. JAMA, 2010; 303:2043–2050.
13.
WeidmannP, BöhlenL, de CourtenM. Insulin resistance and hyperinsulinemia in hypertension. J Hypertens Suppl, 1995; 13:S65–S72.
14.
GressTW, NietoFJ, ShaharE, WoffordMR, BrancatiFL. Hypertension, antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med, 2000; 342:905–912.
15.
PadwalR, LaupacisA. Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care, 2004; 27:247–255.
16.
ElliottWJ, MeyerPM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet, 2007; 369:201–207.
17.
AlmgrenT, WilhelmsenL, SamuelssonO, HimmelmannA, RosengrenA, AnderssonOK. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. J Hypertens, 2007; 25:1311–1317.
18.
DunderK, LindL, ZetheliusB, BerglundL, LithellH. Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study. BMJ, 2003; 326:681.
19.
VerdecchiaP, ReboldiG, AngeliF, BorgioniC, GattobigioR, FilippucciL, NorgioliniS, BraccoC, PorcellatiC. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension, 2004; 43:963–969.
20.
KostisJB, WilsonAC, FreudenbergerRS, CosgroveNM, PresselSL, DavisBR. SHEP Collaborative Research Group: Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol, 2005; 95:29–35.
21.
BarzilayJI, DavisBR, CutlerJA, PresselSL, WheltonPK, BasileJ, MargolisKL, OngST, SadlerLS, SummersonJ. ALLHAT Collaborative Research Group: Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Arch Intern Med, 2006; 166:2191–2201.
22.
KaragiannisA, TziomalosK, PagoureliasED, GossiosTD, AthyrosVG. Effect of antihypertensive drug-associated diabetes on cardiovascular risk. Hellenic J Cardiol, 2010; 51:195–199.
23.
ManciaG, De BackerG, DominiczakA, CifkovaR, FagardR, GermanoG, GrassiG, HeagertyAM, KjeldsenSE, LaurentS, NarkiewiczK, RuilopeL, RynkiewiczA, SchmiederRE, BoudierHA, ZanchettiA, VahanianA, CammJ, De CaterinaR, DeanV, DicksteinK, FilippatosG, Funck-BrentanoC, HellemansI, KristensenSD, McGregorK, SechtemU, SilberS, TenderaM, WidimskyP, ZamoranoJL, ErdineS, KiowskiW, Agabiti-RoseiE, AmbrosioniE, LindholmLH, ViigimaaM, AdamopoulosS, Agabiti-RoseiE, AmbrosioniE, BertomeuV, ClementD, ErdineS, FarsangC, GaitaD, LipG, MallionJM, ManolisAJ, NilssonPM, O'BrienE, PonikowskiP, RedonJ, RuschitzkaF, TamargoJ, van ZwietenP, WaeberB, WilliamsB. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology: 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)J Hypertens, 2007; 25:1105–1187.
24.
FriedewaldWT, LevyRI, FredricksonDS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 18:499–502.
25.
LeveyAS, BoschJP, LewisJB, GreeneT, RogersN, RothD. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med, 1999; 130:461–470.
ZillichAJ, GargJ, BasuS, BakrisGL, CarterBL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension, 2006; 48:219–224.
28.
LithellH, PollareT, BerneC, SaltinB. The metabolic, circulatory response to beta-blockade in hypertensive men is correlated to muscle capillary density. Blood Press, 1992; 1:20–26.
29.
KaragiannisA, TziomalosK, AnagnostisP, GossiosTD, FlorentinM, AthyrosVG, MikhailidisDP. The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis. Curr Vasc Pharmacol, 2010; 8:792–803.
30.
BarzilayJI, DavisBR, PresselSL, CutlerJA, EinhornPT, BlackHR, CushmanWC, FordCE, MargolisKL, MolooJ, OparilS, PillerLB, SimmonsDL, SweeneyME, WheltonPK, WongND, WrightJTJr. ALLHAT Collaborative Research Group: Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Circ Cardiovasc Qual Outcomes, 2012; 5:153–162.
